Outcomes
| . | Overall . | Historical controls . |
|---|---|---|
| Median (range) follow-up for surviving patients, mo | 64.2 (0.4-109.5) | |
| Induction death rate, N (%) | 9 (3) | |
| Response/progression | ||
| M status CR, N (%)* | 263 (89) | |
| 95% exact CI, % | 85-92 | |
| OS | ||
| N of patients | 295 | |
| N of events | 105 | |
| Median (95% CI), mo | NE | 61 (39-89) |
| 3 yr (95% CI), % | 73 (68-78) | 58 (52-64) |
| EFS | ||
| N of patients | 295 | |
| N of events | 139 | |
| Median (95% CI), mo | 78.1 (41.8-NE) | 30 (22-38) |
| 3 yr (95% CI), % | 59 (54-65) | |
| DFS | ||
| N of patients | 263 | |
| N of events | 107 | |
| Median (95% CI), mo | 81.7 (58.4-NE) | 34 (28-50) |
| 3 yr (95% CI), % | 66 (60-72) | 48 (41-55) |
| . | Overall . | Historical controls . |
|---|---|---|
| Median (range) follow-up for surviving patients, mo | 64.2 (0.4-109.5) | |
| Induction death rate, N (%) | 9 (3) | |
| Response/progression | ||
| M status CR, N (%)* | 263 (89) | |
| 95% exact CI, % | 85-92 | |
| OS | ||
| N of patients | 295 | |
| N of events | 105 | |
| Median (95% CI), mo | NE | 61 (39-89) |
| 3 yr (95% CI), % | 73 (68-78) | 58 (52-64) |
| EFS | ||
| N of patients | 295 | |
| N of events | 139 | |
| Median (95% CI), mo | 78.1 (41.8-NE) | 30 (22-38) |
| 3 yr (95% CI), % | 59 (54-65) | |
| DFS | ||
| N of patients | 263 | |
| N of events | 107 | |
| Median (95% CI), mo | 81.7 (58.4-NE) | 34 (28-50) |
| 3 yr (95% CI), % | 66 (60-72) | 48 (41-55) |
NE, not estimable.
Achieved M0 to M1 status by end of induction or extended induction.